ScholarIQanswers from OpenAlex
Hospital Universitario Fundación Jiménez Díaz
InstitutionResearch output, impact & collaborations
Hospital Universitario Fundación Jiménez Díaz is a institution indexed in ScholarIQ from OpenAlex.
What is known about Hospital Universitario Fundación Jiménez Díaz?
ScholarIQrecord summary
Hospital Universitario Fundación Jiménez Díaz is a research organisation in Madrid, ES. OpenAlex records 18,985 works and 1,213,145 citations for it. 5,716 researchers list it as their most recent affiliation.
How many works does Hospital Universitario Fundación Jiménez Díaz have?
ScholarIQindexed works
Hospital Universitario Fundación Jiménez Díaz has 18,985 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Hospital Universitario Fundación Jiménez Díaz have?
ScholarIQcitation count
Hospital Universitario Fundación Jiménez Díaz has 1,213,145 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Hospital Universitario Fundación Jiménez Díaz?
ScholarIQresearcher count
Hospital Universitario Fundación Jiménez Díaz has 5,716 researchers in the ScholarIQ index.
What is the average h-index at Hospital Universitario Fundación Jiménez Díaz?
ScholarIQavg h-index
Hospital Universitario Fundación Jiménez Díaz has an average h-index of 50.6 in OpenAlex.
What is the ROR of Hospital Universitario Fundación Jiménez Díaz?
ScholarIQror
The ROR for Hospital Universitario Fundación Jiménez Díaz is on the source record.
What is the OpenAlex record for Hospital Universitario Fundación Jiménez Díaz?
ScholarIQopenalex
The OpenAlex for Hospital Universitario Fundación Jiménez Díaz is on the source record.
Who are the most-cited researchers behind Hospital Universitario Fundación Jiménez Díaz?
ScholarIQtop researchers by citations
What are the most-cited papers on Hospital Universitario Fundación Jiménez Díaz?
ScholarIQmost cited works
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Paul Baas, Lucio Crinò, Wilfried Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Płużański, Everett E. Vokes, Esther Holgado, David Waterhouse, Neal Ready, Justin F. Gainor, Osvaldo Arén Frontera, Libor Havel, Martin Steins, Marina Chiara Garassino, Joachim G.J.V. Aerts, Manuel Dómine, Luis Paz‐Ares, Martin Reck, Christine Baudelet, Christopher Harbison, Brian Lestini, David R. Spigel
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Dómine, Philip R. Clingan, Maximilian J. Hochmair, Steven Powell, Susanna Y. Cheng, Helge Bischoff, Nir Peled, Francesco Grossi, Ross Jennens, Martin Reck, Rina Hui, Edward B. Garon, Michael Boyer, Belén Rubio‐Viqueira, Silvia Novello, Takayasu Kurata, Jhanelle E. Gray, John Vida, Ziwen Wei, Jing Yang, Harry Raftopoulos, M. Catherine Pietanza, Marina Chiara Garassino
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell, Enric Carcereny, Radj Gervais, A. Vergnenègre, Bartomeu Massutí, Enriqueta Felip, Ramón Palmero, Ramón García-Gómez, Cinta Pallarés, José Miguel Sánchez, Rut Porta, Manuel Cobo, Pilar Garrido, Flavia Longo, Teresa Morán, Amelia Insa, Filippo de Marinis, R. Corre, Isabel Bover, Alfonso Illiano, Éric Dansin, Javier de Castro, Michèle Milella, Noemı́ Reguart, Giuseppe Altavilla, Ulpiano Jiménez, Mariano Provencio, Miguel Ángel Moreno, Josefa Terrasa, José Muñoz-Langa, Javier Valdivia, Dolores Isla, Manuel Dómine, Olivier Molinier, Julien Mazières, Nathalie Baize, Rosario García‐Campelo, G. Robinet, Delvys Rodríguez‐Abreu, Guillermo López-Vivanco, Vittorio Gebbia, Lioba Ferrera-Delgado, P. Bombaron, Reyes Bernabé, Alessandra Bearz, Á. Artal, Enrico Cortesi, Christian Rolfo, María Sanchez-Ronco, Ana Drozdowskyj, Cristina Queralt, Itziar de Aguirre, José Luis Ramírez, José Javier Sánchez, Miguel Ángel Molina‐Vila, Miquel Tarón, Luis Paz‐Ares
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
Yi‐Long Wu, Masahiro Tsuboi, Jie He, Thomas John, Christian Grohé, Margarita Majem, Jonathan W. Goldman, К. К. Лактионов, Sang‐We Kim, Terufumi Kato, Huu-Vinh Vu, Shun Lü, Kye Young Lee, Charuwan Akewanlop, Chong‐Jen Yu, Filippo de Marinis, Laura Bonanno, Manuel Dómine, Frances A. Shepherd, Lingmin Zeng, Rachel Hodge, Ajlan Atasoy, Yuri Rukazenkov, Roy S. Herbst
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer
Shirish M. Gadgeel, Delvys Rodríguez‐Abreu, Giovanna Speranza, Emilio Esteban, Enriqueta Felip, Manuel Dómine, Rina Hui, Maximilian J. Hochmair, Philip R. Clingan, Steven Powell, Susanna Y. Cheng, Helge Bischoff, Nir Peled, Francesco Grossi, Ross Jennens, Martin Reck, Edward B. Garon, Silvia Novello, Belén Rubio‐Viqueira, Michael Boyer, Takayasu Kurata, Jhanelle E. Gray, Jing Yang, Tuba Öcek Baş, M. Catherine Pietanza, Marina Chiara Garassino
How much of the research on Hospital Universitario Fundación Jiménez Díaz is open access?
ScholarIQopen access share
92%OPEN ACCESS